957059-61-9

Usage

Uses

Used in Pharmaceutical Research:
(4-Fluoro-1-benzothiophen-2-yl)methanol is used as a building block in the pharmaceutical industry for the development of new drugs and therapies. Its potent biological activity and unique chemical structure make it a promising candidate for the creation of novel molecules with various pharmacological properties.
Used in Organic Synthesis:
In the field of organic chemistry, (4-Fluoro-1-benzothiophen-2-yl)methanol is used as a key component in the synthesis of complex organic compounds. Its fluoro substitution and benzothiophene core contribute to the diversity of molecules that can be synthesized, making it a valuable asset in the development of new chemical entities.
Used in Neuroprotective Applications:
(4-Fluoro-1-benzothiophen-2-yl)methanol is studied for its potential neuroprotective effects, which could be beneficial in the treatment of neurological disorders and conditions. Its ability to protect neurons and promote brain health makes it a promising candidate for further research and development in this area.
Used in Anticonvulsant Applications:
Additionally, (4-Fluoro-1-benzothiophen-2-yl)methanol has been investigated for its potential anticonvulsant effects, which could be useful in the management of seizure disorders and other conditions related to abnormal electrical activity in the brain. Its ability to reduce seizure activity and protect against convulsions makes it a valuable compound for further exploration in this field.

Upstream product

• 220180-55-2 methyl 4-fluorobenzo[b]thiophene-2-carboxylate 
• 310466-37-6 4-fluoro-1-benzothiophene-2-carboxylic acid 
• 437-81-0 2,6-difluorobenzaldehyde 

Downstream Products

• 1061606-30-1 3-(4-fluoro-benzo[b]thiophen-2-ylmethoxy)-phthalic acid dimethyl ester 
• 1061606-33-4 3-(4-fluoro-benzo[b]thiophen-2-ylmethoxy)-phthalic acid 

Relevant academic research and scientific papers

Development and Process Intensification of an Efficient Flow-Cascade Reaction Sequence in the Synthesis of Afizagabar

Aromatic nitration and catalytic hydrogenation are among the most dangerous reactions in the chemical industry. The traditional, batchwise pilot plant manufacturing process of a key intermediate of our drug candidate afizagabar (S44819) involved these kinds of transformations (besides a Dakin-West-type reaction, a ring closure, and a keto reduction step). To mitigate some of the hazards associated with this sequence, a flow chemical approach was developed. First, a flow-cascade process was elaborated, which furnished the product with a throughput of 1.52 g/h with an HPLC purity of 95.6%. The bottleneck of the procedure in terms of output was the heterogeneous catalytic hydrogenation; therefore, our subsequent process intensification efforts primarily concentrated on this step. Finally, application of higher concentrations and an upscaled hydrogenation reactor combined with the corresponding adjustment of parameters of further reaction steps resulted in an efficient process with an effective product yield of 11.95 g/h and an increased HPLC purity (97.1%). The 4-step uninterrupted process described here is based on a newly developed heterogeneous flow reactor system and a custom-made liquid-liquid extractor, providing an instructive case study on handling hazardous processes in a safe and efficient way.

COLD MENTHOL RECEPTOR-1 ANTAGONISTS

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

COLD MENTHOL RECEPTOR-1 ANTAGONISTS

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

COLD MENTHOL RECEPTOR-1 ANTAGONISTS

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.